I-Mab
IMABDrugs in Pipeline
4
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
TJ003234
Coronavirus Disease 2019 COVID-19
TJ301 300mg
Active Ulcerative Colitis
TJ004309
Ovarian Cancer
Givastomig
Solid Tumor
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
TJ003234 | Phase 3 | Coronavirus Disease 2019 COVID-19 | - | - |
TJ301 300mg | Phase 2 | Active Ulcerative Colitis | - | - |
TJ004309 | Phase 2 | Ovarian Cancer | - | - |
Givastomig | Phase 2 | Solid Tumor | - | - |
Frequently asked questions
What is in I-Mab's drug pipeline?→
CatalystAlert tracks 4 drug candidates in I-Mab's (IMAB) pipeline across Phase 3, Phase 2. Its lead program is TJ003234 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is I-Mab's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for I-Mab (IMAB) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track IMAB biotech catalysts?→
Add IMAB to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow I-Mab's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.